HEART TEST LABORATORIES, INC. Financials Heart Test Laboratories, Inc.
Equities
HSCS
US42254E3027
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.5 USD | -19.24% |
|
-11.29% | -67.84% |
Valuation
| Fiscal Period: April | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 8.644 | 3.606 | - | - |
| Enterprise Value (EV) 1 | 8.55 | 3.606 | 3.606 | 3.606 |
| P/E ratio | -1.11 x | -0.28 x | -0.52 x | - |
| Yield | - | - | - | - |
| Capitalization / Revenue | 1,678 x | 60.8 x | 1.9 x | 0.31 x |
| EV / Revenue | 1,678 x | 60.8 x | 1.9 x | 0.31 x |
| EV / EBITDA | -1.42 x | -0.58 x | -0.42 x | -11.1 x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | 30.6 x | 0.39 x | - | - |
| Nbr of stocks (in thousands) | 97.4 | 655.6 | - | - |
| Reference price 2 | 88.75 | 5.500 | 5.500 | 5.500 |
| Announcement Date | 19/07/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: April | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 0.00515 | 0.0593 | 1.9 | 11.5 |
| EBITDA 1 | - | -6.086 | -6.236 | -8.674 | -0.326 |
| EBIT 1 | - | -6.113 | -6.31 | -8.802 | -0.35 |
| Operating Margin | - | -1,18,698.25% | -10,640.73% | -463.29% | -3.04% |
| Earnings before Tax (EBT) 1 | - | -6.354 | -6.686 | -9.039 | -0.35 |
| Net income 1 | -4.828 | -6.354 | -6.686 | -9.039 | -0.35 |
| Net margin | - | -1,23,384.27% | -11,274.37% | -475.76% | -3.04% |
| EPS 2 | -145.0 | -80.00 | -20.00 | -10.50 | - |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 29/07/22 | 19/07/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: April | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.0032 | - | 0.00195 | - | - | - | 0.0147 | 0.05 | 0.2 | 0.4 | 0.55 | 0.8 |
| EBITDA 1 | - | -1.768 | -1.302 | -1.592 | -1.323 | -1.562 | -1.522 | -1.888 | -2.228 | -2.208 | -2.368 | -1.92 |
| EBIT 1 | -1.43 | -1.775 | -1.309 | -1.599 | -1.331 | -1.57 | -1.525 | -1.9 | -2.248 | -2.228 | -2.388 | -1.94 |
| Operating Margin | -44,690.62% | - | -67,143.59% | - | - | - | -10,376.73% | -3,800% | -1,123.75% | -556.88% | -434.09% | -242.5% |
| Earnings before Tax (EBT) 1 | -1.573 | -1.807 | -1.342 | -1.632 | -1.367 | -1.748 | -1.644 | -1.959 | -2.307 | -2.287 | -2.447 | -1.999 |
| Net income 1 | -1.573 | -1.807 | -1.342 | -1.632 | -1.367 | -1.748 | -1.644 | -1.959 | -2.307 | -2.287 | -2.447 | -1.999 |
| Net margin | -49,165.62% | - | -68,826.67% | - | - | - | -11,182.38% | -3,918.4% | -1,153.35% | -571.68% | -444.85% | -249.9% |
| EPS 2 | -19.25 | -22.00 | -16.00 | -16.00 | -13.00 | -16.00 | -3.000 | -3.500 | -3.000 | -3.000 | -3.000 | -2.000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 12/09/22 | 15/12/22 | 16/03/23 | 19/07/23 | 14/09/23 | 14/12/23 | 14/03/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: April | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | 0.09 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share 2 | - | 2.900 | 14.00 | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | 0.02 | - | - | - |
| Capex / Sales | - | 355.53% | - | - | - |
| Announcement Date | 29/07/22 | 19/07/23 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.5
USD
Average target price
67.5
USD
Spread / Average Target
+1,127.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -67.84% | 44.65L | |
| -17.59% | 274.13Cr | |
| +2.53% | 19Cr | |
| -16.53% | 7.98Cr |
- Stock Market
- Equities
- HSCS Stock
- Financials Heart Test Laboratories, Inc.
